Cepheid Receives New Coverage from Analysts at Wells Fargo & Co. (CPHD)
Equities research analysts at Wells Fargo & Co. initiated coverage on shares of Cepheid (NASDAQ:CPHD) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.
Several other analysts have also recently commented on the stock. Analysts at Craig Hallum upgraded shares of Cepheid from a “sell” rating to a “hold” rating in a research note on Monday, June 9th. Separately, analysts at SunTrust reiterated a “neutral” rating on shares of Cepheid in a research note on Monday, June 9th. They now have a $49.00 price target on the stock, down previously from $54.00. Finally, analysts at Needham & Company LLC upgraded shares of Cepheid from a “hold” rating to a “buy” rating in a research note on Tuesday, May 27th. They now have a $50.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $52.00.
In other Cepheid news, EVP Kerry Flom unloaded 1,282 shares of Cepheid stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $48.97, for a total transaction of $62,779.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Cepheid (NASDAQ:CPHD) traded up 1.08% on Wednesday, hitting $47.75. 350,776 shares of the company’s stock traded hands. Cepheid has a one year low of $30.95 and a one year high of $55.89. The stock has a 50-day moving average of $45.93 and a 200-day moving average of $47.99. The company’s market cap is $3.329 billion.
Cepheid (NASDAQ:CPHD) last issued its quarterly earnings data on Thursday, April 17th. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.17) by $0.16. The company had revenue of $106.90 million for the quarter, compared to the consensus estimate of $104.90 million. During the same quarter last year, the company posted $0.11 earnings per share. Cepheid’s revenue was up 16.3% compared to the same quarter last year. Analysts expect that Cepheid will post $-0.34 EPS for the current fiscal year.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.